Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients.

ABSTRACT:

Introduction

Blood product transfusion retains a critical role in the supportive care of patients with acute myeloid leukemia (AML). Whereas previous studies have shown increased transfusion dependency to portend inferior outcome, predictive factors of an increased transfusion burden and the prognostic impact of transfusion support have not been assessed recently.

Methods/patients

We performed a retrospective analysis on a recent cohort of patients given intensive induction chemotherapy in 2014-2022.

Results

The analysis comprised 180 patients with a median age of 57 years with 80% designated as de novo AML. Fifty-four patients (31%) were FLT3-ITD mutated, and 73 patients (42%) harbored NPM1. Favorable risk and intermediate risk ELN 2017 patients account

SUBMITTER: Miller L 

PROVIDER: S-EPMC10601600 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature